BiotechTube

LDK378

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Normal Hepatic Function

Conditions

Normal Hepatic Function, Impaired Hepatic Function

Trial Timeline

Jan 1, 2014 → Sep 1, 2016

NCT ID
NCT01950481

About LDK378

LDK378 is a phase 1 stage product being developed by Novartis for Normal Hepatic Function. The current trial status is completed. This product is registered under clinical trial identifier NCT01950481. Target conditions include Normal Hepatic Function, Impaired Hepatic Function.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (8)

NCT IDPhaseStatus
NCT01947608Pre-clinicalCompleted
NCT02450903Phase 2Completed
NCT02040870Phase 1/2Completed
NCT01950481Phase 1Completed
NCT01685138Phase 2Completed
NCT01685060Phase 2Completed
NCT01634763Phase 1Completed
NCT01283516Phase 1Completed

Competing Products

20 competing products in Normal Hepatic Function

See all competitors
ProductCompanyStageHype Score
RoxadustatAstellas PharmaPhase 1
33
DonepezilEisaiApproved
85
eribulin mesylateEisaiPhase 2
52
Lurasidone HClSumitomo PharmaPhase 1
33
Eybelis ophthalmic solution 0.002%Santen PharmaceuticalApproved
85
TriptorelinMerckPre-clinical
23
Temozolomide + VorinostatMerckPhase 2
52
LDE225NovartisPhase 1
33
LDK378NovartisPhase 1
33
cyclosporine micro-emulsionNovartisApproved
85
LEE011NovartisPhase 1
33
LEE011NovartisPhase 1
33
mycophenolate mofetilRochePhase 1
33
filgrastimAmgenPre-clinical
22
PF-06423264PfizerPhase 1
32
PF-05221304PfizerPhase 1
32
BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose SolutionBristol Myers SquibbPhase 1
32
tolebrutinibSanofiPhase 1
32
Venglustat (GZ402671)SanofiPhase 1
32
RilzabrutinibSanofiPhase 1
32

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85